(Q44443788)

3 December 2017

title

Predictive value of tumour cell proliferation in locally advanced breast cancer treated with neoadjuvant chemotherapy (English)

1 reference

3 December 2017

1 reference

5

Varhaug JE

1 reference

3 December 2017

11

Lønning PE

1 reference

3 December 2017

Anne-Lise Børresen-Dale

series ordinal

9

object named as

Børresen-Dale AL

1 reference

3 December 2017

10

Akslen LA

1 reference

3 December 2017

3

Eide GE

1 reference

3 December 2017

2

Geisler S

1 reference

3 December 2017

7

Thorsen T

1 reference

3 December 2017

1

Aas T

1 reference

3 December 2017

4

Haugen DF

1 reference

3 December 2017

Bassøe AM

6

1 reference

3 December 2017

Berntsen H

series ordinal

8

1 reference

3 December 2017

language of work or name

1 reference

1 March 2003

1 reference

European Journal of Cancer

3 December 2017

published in

1 reference

3 December 2017

volume

39

1 reference

3 December 2017

issue

4

1 reference

3 December 2017

page(s)

438-446

1 reference

Growth rate patterns of solid tumors and their relation to responsiveness to therapy: an analytical review

3 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900732-3

7 January 2021

erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900732-3

7 January 2021

erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900732-3

7 January 2021

p53-dependent apoptosis modulates the cytotoxicity of anticancer agents

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900732-3

7 January 2021

p53 status and the efficacy of cancer therapy in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900732-3

7 January 2021

Clinical significance of p53 mutations in newly diagnosed Burkitt's lymphoma and acute lymphoblastic leukemia: a report of 48 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900732-3

7 January 2021

Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900732-3

7 January 2021

Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900732-3

7 January 2021

Primary systemic treatment with weekly doxorubicin monotherapy in women with locally advanced breast cancer; clinical experience and parameters predicting outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900732-3

7 January 2021

Assessment of response to therapy in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900732-3

7 January 2021

Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900732-3

7 January 2021

Prognostic significance of angiogenesis and Ki-67, p53, and p21 expression: a population-based endometrial carcinoma study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900732-3

7 January 2021

The Proof and Measurement of Association between Two Things

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900732-3

7 January 2021

On a Test of Whether one of Two Random Variables is Stochastically Larger than the Other

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900732-3

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900732-3

7 January 2021

Mutations in exons 5-8 of the p53 gene, independent of their type and location, are associated with increased apoptosis and mitosis in invasive breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900732-3

7 January 2021

Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900732-3

7 January 2021

Expression of Bcl-2, but not Bax, correlates with estrogen receptor status and tumor proliferation in invasive breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900732-3

7 January 2021

Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900732-3

7 January 2021

Cell proliferation as a predictor of response to chemotherapy in metastatic breast cancer: A prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900732-3

7 January 2021

Primary chemotherapy in locally advanced breast cancer (LABC): effects on tumour proliferative activity, bcl-2 expression and the relationship between tumour regression and biological markers

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900732-3

7 January 2021

Prediction of response to primary chemotherapy for operable breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900732-3

7 January 2021

Changes in biological markers after primary chemotherapy for breast cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900732-3

7 January 2021

Expression of drug resistance proteins in breast cancer, in relation to chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900732-3

7 January 2021

Changes of biological features in breast cancer cells determined by primary chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900732-3

7 January 2021

Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900732-3

7 January 2021

Proliferating fraction during neoadjuvant chemotherapy of primary breast cancer in relation to objective local response and relapse-free survival

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900732-3

7 January 2021

Biological markers as indicators of response to primary and adjuvant chemotherapy in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900732-3

7 January 2021

Tumor proliferative activity and response to first-line chemotherapy in advanced breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900732-3

7 January 2021

Predictive value of c-erbB-2, p53, cathepsin-D and histology of the primary tumour in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900732-3

7 January 2021

c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900732-3

7 January 2021

Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900732-3

7 January 2021

Bcl-2 protein expression in breast cancer in relation to established prognostic factors and other clinicopathological variables

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900732-3

7 January 2021

Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled, open phase IIb study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900732-3

7 January 2021

Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900732-3

7 January 2021

10.1016/S0959-8049(02)00732-3

Identifiers

DOI

1 reference

3 December 2017

1 reference